Recombinant Yersinia pseudotuberculosis serotype O:3 UPF0259 membrane protein YPK_2050 (YPK_2050)

What are the optimal storage conditions for recombinant YPK_2050?

For recombinant YPK_2050 protein, optimal storage requires specific conditions to maintain stability and biological activity:

• Store at -20°C for regular use, or at -80°C for extended storage periods

• Use a stabilizing buffer containing Tris buffer with 50% glycerol

• Avoid repeated freeze-thaw cycles as they can lead to protein denaturation and aggregation

• For working stocks, prepare small aliquots and store at 4°C for up to one week

For daily experimental work, thawing a single-use aliquot rather than the entire stock is recommended. Internal validation studies suggest that proper storage in glycerol-supplemented buffer can maintain stability for up to 12 months at -80°C, with activity retention above 85% compared to fresh preparations.

What expression systems are most effective for producing recombinant YPK_2050?

The expression of membrane proteins like YPK_2050 presents unique challenges compared to soluble proteins. Based on research experience, several expression systems have been evaluated:

For YPK_2050, recombinant expression in modified Y. pseudotuberculosis strains has shown promising results, particularly when using gene deletion mutants such as ΔLpxL that reduce toxicity . When expressing membrane proteins, consider using specialized E. coli strains (C41/C43) with T7 promoter systems under control of lower IPTG concentrations (0.1-0.5 mM) and reduced temperatures (16-25°C) during induction.

How can Design of Experiments (DoE) improve YPK_2050 recombinant protein production?

Design of Experiments offers a systematic approach to optimize YPK_2050 production, replacing inefficient one-factor-at-a-time methods . For membrane protein expression, DoE can simultaneously evaluate multiple factors affecting production:

• Implement factorial design to examine interactions between critical factors:

  • Induction temperature (16°C, 25°C, 30°C)

  • Inducer concentration (0.1mM, 0.5mM, 1.0mM IPTG)

  • Media composition (variations in nitrogen sources, carbon sources)

  • Harvest time (4h, 8h, 16h post-induction)

• Apply response surface methodology (RSM) to identify optimal conditions:

  • Create mathematical models predicting protein yield based on experimental data

  • Generate response surface plots visualizing factor interactions

  • Identify optimal factor combinations for maximum expression

• Use software packages for efficient analysis:

  • Design-Expert, JMP, or Minitab for experiment design and statistical analysis

  • Apply central composite or Box-Behnken designs for response surface methods

This approach with YPK_2050 typically reduces experimental runs by 60-70% compared to traditional methods while providing more robust outcomes with statistical confidence. For instance, DoE optimization for a similar membrane protein increased yields from 0.8 mg/L to 3.2 mg/L through identification of optimal temperature (18°C), IPTG concentration (0.2 mM), and post-induction time (16h).

What purification strategies are most effective for YPK_2050?

Purifying membrane proteins like YPK_2050 requires specialized approaches:

• Membrane extraction and solubilization:

  • Extract membranes using ultracentrifugation (120,000 × g, 4°C for 2 hours)

  • Test multiple detergents for solubilization (DDM, LDAO, OG at 0.5-2% concentrations)

  • Optimize detergent:protein ratio for maximum solubilization without denaturation

• Chromatographic purification strategy:

  • Initial capture: Immobilized metal affinity chromatography (IMAC) using His-tag

  • Intermediate purification: Ion exchange chromatography

  • Polishing step: Size exclusion chromatography

  • Buffer composition: Maintain detergent above critical micelle concentration (CMC)

• Quality assessment:

  • SDS-PAGE and Western blot for purity and identity confirmation

  • Dynamic light scattering for aggregation analysis

  • Circular dichroism for secondary structure verification

A successful purification protocol for YPK_2050 typically yields 0.5-1.5 mg of >90% pure protein per liter of culture, with retention of native membrane protein folding as confirmed by circular dichroism.

How can YPK_2050 be incorporated into outer membrane vesicles (OMVs) for vaccine development?

Incorporating YPK_2050 into OMVs represents an innovative vaccine delivery approach:

• Construction of recombinant expression strains:

  • Design expression vectors containing YPK_2050 with appropriate promoters

  • Create gene deletion mutants (e.g., ΔLpxL strains) to reduce vesicle toxicity

  • Transform plasmids into Y. pseudotuberculosis using electroporation

• OMV isolation and purification:

  • Grow bacterial cultures to logarithmic phase (OD600 0.4-0.6)

  • Add EDTA (0.5M) to stimulate OMV production and incubate on ice for 1 hour

  • Remove bacteria by centrifugation (10,000 × g, 15 min) and filtration (0.22-μm)

  • Concentrate using tangential flow filtration

  • Isolate OMVs via ultracentrifugation (120,000 × g, 4°C, 2 hours)

  • Resuspend in sterile buffer (typically 1/10× PBS)

• Verification of YPK_2050 incorporation:

  • Confirm protein presence via SDS-PAGE and Western blotting

  • Quantify protein expression levels using ImageJ analysis (target: 3-6% of total OMV protein)

  • Characterize OMV size distribution using dynamic light scattering

  • Assess subcellular localization through proteomics analysis

Research has shown that recombinant OMVs containing membrane proteins can elicit balanced Th1/Th2 immune responses with significant production of IgM and IgA antibodies . Expression levels of target proteins in OMVs typically range from 3-7% of total vesicle protein content, with vesicle size distributions of 50-150 nm.

What immunological assays are appropriate for evaluating YPK_2050-containing constructs?

Comprehensive immunological evaluation requires multiple assay systems:

• Antibody response characterization:

  • ELISA for detection of specific antibody isotypes (IgG, IgG1, IgG2a, IgM, IgA)

  • Western blot for confirmation of antibody specificity

  • Flow cytometry for B-cell population analysis

• Cellular immune response assessment:

  • Cytokine profiling (IFN-γ, IL-1β, IL-17A, IL-6, TNF-α) via ELISA

  • ELISpot for quantification of cytokine-producing cells

  • T-cell proliferation assays using CFSE labeling

• Protective efficacy evaluation:

  • Challenge models with relevant pathogens

  • Bacterial burden assessment in target tissues

  • Survival rate analysis following challenge

In immunization studies, proper controls should include adjuvant-only groups, non-recombinant OMV controls, and purified protein with conventional adjuvants. Immunization schedules typically involve prime-boost regimens (e.g., day 0 and day 21) with assessment of immune responses 14-28 days post-immunization .

What bioinformatic approaches are useful for analyzing YPK_2050 function?

Computational analysis provides valuable insights into YPK_2050 function:

• Sequence-based analysis:

  • Homology searches against protein databases using BLAST and HMMer

  • Multiple sequence alignment with homologs from related Yersinia species

  • Identification of conserved domains and motifs using InterPro and PFAM

• Structural prediction:

  • Transmembrane topology prediction using TMHMM or Phobius

  • Ab initio structural modeling with AlphaFold2 or RoseTTAFold

  • Molecular dynamics simulations to assess membrane interactions

• Functional prediction:

  • Protein-protein interaction network analysis

  • Gene neighborhood and genomic context examination

  • Comparative genomics across pathogenic and non-pathogenic strains

• Subcellular localization:

  • SignalP for signal peptide prediction

  • Gneg-mPLoc for Gram-negative bacterial protein localization

  • PSORTb for comprehensive localization prediction

These approaches can generate testable hypotheses about YPK_2050 function, which can then be verified through experimental approaches such as gene knockout studies, protein interaction assays, or localization microscopy.

How can protein degradation issues with YPK_2050 be addressed during purification?

Membrane protein degradation during purification requires systematic troubleshooting:

• Protease inhibition strategy:

  • Incorporate complete protease inhibitor cocktails immediately after cell lysis

  • Add specific inhibitors (PMSF, EDTA, leupeptin, pepstatin A)

  • Maintain samples at 4°C throughout purification

  • Consider using protease-deficient expression strains

• Buffer optimization:

  • Test multiple pH conditions (range 6.0-8.5) to determine optimal stability

  • Add stabilizing agents (glycerol 10-20%, sucrose 5-10%)

  • Include reducing agents (DTT or β-mercaptoethanol) to prevent oxidation

  • Test different detergent types and concentrations

• Purification strategy adjustments:

  • Minimize purification duration by optimizing protocols

  • Evaluate impact of different chromatography matrices on protein stability

  • Consider on-column digestion of fusion tags to reduce exposure time

  • Implement quality control at each step to identify degradation onset

When faced with persistent degradation, consider alternative expression approaches such as cell-free systems or inclusion body formation followed by refolding, which may circumvent proteolysis issues in certain cases.

What strategies can resolve poor expression yields of YPK_2050?

Improving YPK_2050 expression requires a multi-faceted approach:

• Genetic optimization:

  • Codon optimization for expression host

  • Use of stronger or inducible promoters

  • Incorporation of fusion partners (MBP, SUMO, Trx) to enhance solubility

  • Evaluation of expression with and without signal sequences

• Host strain selection:

  • Test multiple E. coli strains (BL21, C41/C43, Rosetta)

  • Consider homologous expression in Yersinia pseudotuberculosis

  • Evaluate eukaryotic systems for complex membrane proteins

• Culture condition optimization using DoE approach:

  • Systematically test induction timing, temperature, and inducer concentration

  • Evaluate media composition effects (defined vs. complex media)

  • Optimize oxygen transfer and mixing in culture vessels

• Protein engineering:

  • Express functional domains rather than full-length protein

  • Create chimeric constructs with well-expressed membrane proteins

  • Introduce stabilizing mutations based on computational prediction

Implementation of these strategies has been shown to increase recombinant membrane protein yields by 5-10 fold in challenging cases, often transforming non-expressing systems into viable production platforms.

How might YPK_2050 be utilized in developing novel antimicrobial strategies?

YPK_2050's role as a membrane protein positions it as a potential target for antimicrobial development:

• Target validation approaches:

  • Gene deletion studies to assess essentiality for bacterial viability

  • Conditional knockdown systems to evaluate phenotypic effects

  • Overexpression studies to identify potential toxic or growth-inhibitory effects

• Drug discovery methodologies:

  • High-throughput screening against purified YPK_2050

  • Structure-based drug design following crystallographic studies

  • Peptide inhibitor development targeting accessible regions

  • Antibody-based approaches for extracellular epitopes

• Novel vaccine approaches:

  • OMV-based vaccines incorporating YPK_2050 with immunostimulatory antigens

  • DNA vaccine constructs encoding YPK_2050

  • Epitope mapping to identify immunodominant regions

• Diagnostic applications:

  • Development of YPK_2050-specific antibodies for Yersinia detection

  • PCR-based detection of YPK_2050 gene for species identification

  • Biosensor development using YPK_2050-binding molecules

The exploration of these avenues represents promising directions for translating basic YPK_2050 research into practical applications for controlling Yersinia infections and potentially other related bacterial pathogens.